207_Combined course Presentations

Phase III trials – Investigating Oxaliplatin

Fluoropyrimidine Platform

Trial

Eligibility

CAO/ARO/AIO-04 <12cm from anal verge

5FU 1000mg/2 X 5 days 1-5 + 29-33

T3/T4 cN0/N+ TRUS, CT and/or MRI

NSABP R04 N=1606

<12cm; resectable stage II, III TRUS or MRI – CT if T4/ N1-2

PVI 5FU vs Capecitabine

FFCD N=598

Palpable; resectable; T3/4 N0-2; T2 distal anterior

Capecitabine in both arms

STAR – 01 N=747

Resectable stage II, III (c stage) <12cm from anal verge

PVI 5FU in both arms

PETTAC 6 N=1090

Stage II or III resectable or expected to become resectable <12cm from anal verge

Capecitabine in both arms